IntelliProve, a Ghent-based healthtech company, has closed a €2.7 million seed round led by Miles Ahead to scale its camera-based vital-sign detection system into humanoid robots. The funding also drew participation from home nursing organisation Wit-Gele Kruis, the imec.istart Fund, and several business angels.
The startup's technology extracts heart rate, heart rate variability, breathing rate, and blood pressure from a 30-second facial scan using nothing more than a standard camera—no cuff required. The software is already embedded in care apps, insurance platforms, and wellbeing services across more than 50 countries.
This funding round allows us to invest in technology and growth. We can open conversations with robotics companies and virtual care partners worldwide, while doubling down on the data and certification that make all of it possible. Our ambition is simple: a health sensing layer that care can rely on, on any camera.
Joeri Tulkens, co-CEO of IntelliProve
Splitting the budget three ways
The €2.7 million allocation breaks down into three roughly equal portions, according to Tulkens. One third targets regulatory compliance and certification, another third funds additional research, and the final third supports commercial expansion, including robot deployments.
IntelliProve already holds CE marking as a Class I medical device under EU Medical Device Regulation, covering its core signal acquisition engine. The company is now pursuing Class IIa certification, though it declined to specify which measurements would fall under that classification.
The publicly available scan on IntelliProve's website offers a lighter version for developers, returning heart rate, HRV, and respiratory rate. Blood pressure measurements remain available exclusively to integration partners, Tulkens noted.
The technology behind the scan
IntelliProve employs remote photoplethysmography, or rPPG, a technique that detects minute colour shifts in facial skin caused by each heartbeat. The company's software tracks facial movement, isolates the pulse signal, and calculates blood pressure by analyzing pulse wave morphology using a proprietary deep learning model.
The models have been trained and validated against more than 6 million data points. In internal testing, 97.6% of heart rate measurements stayed within five beats per minute of reference devices, according to the company's materials.
IntelliProve collaborates with TU Delft, Ghent University Hospital, and Wit-Gele Kruis on development and validation.
Expanding from phones into robotic platforms
The startup envisions deploying its scanning capability within humanoid robots entering residential and clinical settings. The robotics sector has attracted substantial investor interest, with funding rounds ranging from Agile Robots' $500 million to Minerva Humanoids' pre-seed stage. A robot equipped with cameras could perform the scan using hardware already integrated into its design, then relay the measurements to a human operator for decision-making.
IntelliProve confirmed it is already working with select robotics partners, though declined to disclose their identities. The funding will also support data collection across diverse skin tones, age groups, lighting conditions, and device types, as well as certification efforts outside Europe.
Whether the scan runs on a smartphone or on a humanoid robot, the bar stays the same.
Tanguy Sanglet, co-founder and CTO of IntelliProve
Source: The Next Web



